Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth.

MLA

Ma, Xun, et al. “Daratumumab Binds to Mobilized CD34+ Cells of Myeloma Patients in Vitro without Cytotoxicity or Impaired Progenitor Cell Growth.” Experimental Hematology & Oncology, vol. 7, Oct. 2018, p. 27. EBSCOhost, https://doi.org/10.1186/s40164-018-0119-4.

APA

Ma, X., Wong, S. W., Zhou, P., Chaulagain, C. P., Doshi, P., Klein, A. K., Sprague, K., Kugelmass, A., Toskic, D., Warner, M., Miller, K. B., Lee, L., Varga, C., & Comenzo, R. L. (2018). Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth. Experimental Hematology & Oncology, 7, 27. https://doi.org/10.1186/s40164-018-0119-4

Chicago

Ma, Xun, Sandy W Wong, Ping Zhou, Chakra P Chaulagain, Parul Doshi, Andreas K Klein, Kellie Sprague, et al. 2018. “Daratumumab Binds to Mobilized CD34+ Cells of Myeloma Patients in Vitro without Cytotoxicity or Impaired Progenitor Cell Growth.” Experimental Hematology & Oncology 7 (October): 27. doi:10.1186/s40164-018-0119-4.